← Back to Search

Integrated Care Management for Lupus (Rheum-iCMP Trial)

N/A

Waitlist Available

Led By Candace H Feldman, MD, ScD

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months prior to intervention compared to the 12 months during the intervention, beginning at the start of the intervention

Awards & highlights

Rheum-iCMP Trial Summary

This trialwill study lupus patients at BWH to identify those at high risk of adverse outcomes, and offer intensive care management to reduce avoidable ED visits, hospitalizations and improve high quality care.

Who is the study for?

This trial is for lupus patients at Brigham and Women's Hospital who've had a hospital visit or missed an appointment in the last 3 years, get their primary care there, and meet specific lupus diagnosis criteria. It's not open to those who don't speak English or Spanish.Check my eligibility

What is being tested?

The study tests an intensive care management program (Rheum iCMP) involving a nurse manager for high-risk lupus patients. The goal is to see if it improves regular outpatient care and reduces unnecessary emergency visits and hospital stays.See study design

What are the potential side effects?

Since this trial involves a care management program rather than medication, traditional side effects are not applicable. However, participants may experience changes in healthcare delivery that could affect their routine.

Rheum-iCMP Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months prior to intervention compared to the 12 months during the intervention, beginning at the start of the intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months prior to intervention compared to the 12 months during the intervention, beginning at the start of the intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months prior to intervention compared to the 12 months during the intervention, beginning at the start of the intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Composite measure of acute care utilization

Lupus-related appointment nonadherence

Quality of Lupus Care: SLE Quality Metric Scoring System for Adults

Secondary outcome measures

Beliefs About Medications Survey

Everyday Discrimination Scale

Medication Adherence Self-Report Inventory (MASRI)

+4 more

Rheum-iCMP Trial Design

2Treatment groups

Experimental Treatment

Group I: Rheum iCMP Wave 2Experimental Treatment1 Intervention

20 patients enrolled in Rheum iCMP after 4 months; will receive monthly lupus educational materials mailed to their home during the first 4 months

Group II: Rheum iCMP Wave 1Experimental Treatment1 Intervention

20 patients enrolled immediately in Rheum iCMP

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor

1,611 Previous Clinical Trials

11,470,379 Total Patients Enrolled

2 Trials studying Lupus

408 Patients Enrolled for Lupus

Partners HealthCareOTHER

14 Previous Clinical Trials

54,999 Total Patients Enrolled

Candace H Feldman, MD, ScDPrincipal InvestigatorBrigham and Women's Hospital

2 Previous Clinical Trials

247 Total Patients Enrolled

Media Library

Rheum iCMP Clinical Trial Eligibility Overview. Trial Name: NCT03915652 — N/A

Lupus Research Study Groups: Rheum iCMP Wave 1, Rheum iCMP Wave 2

Lupus Clinical Trial 2023: Rheum iCMP Highlights & Side Effects. Trial Name: NCT03915652 — N/A

Rheum iCMP 2023 Treatment Timeline for Medical Study. Trial Name: NCT03915652 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What purpose does this clinical experiment hope to accomplish?

"The purpose of this trial, observed for a period of 12 months before and during the intervention, is to assess the Quality of Lupus Care - SLE Quality Metric Scoring System for Adults. Secondary outcomes include an evaluation on Change in social determinants of health from baseline to 12months using the Partners Healthcare SDH Survey (with no numerical scoring system), Change in global health from baseline to 12 months using PROMIS global health scale short form (scores range 9-45 with higher scores indicating better outcome) and lastly Change in MASRI score (for lupus medications) from baseline to12 months (score range 0"

Answered by AI

Is this trial currently accepting participants?

"According to the clinicaltrials.gov records, this medical trial has concluded its recruitment phase and is no longer seeking applicants. The initial posting date was June 21st 2019 with an edit on November 16th 2022, however there are 125 other trials actively recruiting patients at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Addressing Disparities in Lupus Care Through an Integrated Care Management Program

Candace Hillary Feldman, MD 2019. "Addressing Disparities in Lupus Care Through an Integrated Care Management Program". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03915652.

All > Lupus